托利帕利马布加化学放射治疗治疗复发性鼻癌:一个单臂的2期临床试验
Zhehao Xiao1, Zhongguo Liang1, Hejing Huang1
1Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Cancer
|January 18, 2026
概括
托里帕利马布与化疗放射治疗结合,对复发性鼻癌 (rNPC) 显示出显著的疗效. 然而,致命性表的高率需要对这种治疗进行仔细的风险效益评估.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 辐射瘤学 辐射瘤学
背景情况:
- 局部复发性鼻癌 (rNPC) 需要改进的再治疗策略,以提高患者的生存率.
- 一种免疫疗法药物托里帕利马布 (toripalimab) 正在研究其治疗rNPC的潜力.
研究的目的:
- 评估托利帕利马布与rNPC患者同时进行化学放射治疗 (CCRT) 的疗效和安全性.
主要方法:
- 一个单臂的2期临床试验进行了.
- 组织学或放射学证实rNPC的患者接受了toripalimab加CCRT.
- 主要终点是客观应答率 (ORR);次要终点包括疾病控制率 (DCR),无进展生存率 (PFS),总生存率 (OS) 和安全.
主要成果:
- 这项研究招募了40名患有rNPC的患者.
- 客观应答率 (ORR) 为87.5%,疾病控制率 (DCR) 为100%.
- 无进展生存时间 (PFS) 中位数为18.1个月,总生存时间 (OS) 中位数为28.3个月. 血液毒性很常见,致命的表发生在22.5%的患者中.
结论:
- 托里帕利马布加CCRT在rNPC中显示出显著的抗瘤活性.
- 致命性表发生率高 (22.5%) 是一个关键的安全问题,需要仔细考虑治疗的益处.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
597
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
597
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K